Raltitrexed

CHEMBL225071 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

458.5 g/mol

LogP

1.4

Phase

4

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

Molekularmasse

458,5000 g/mol

LogP

1,40

TPSA

177,00 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pancreatic Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1

InChI

InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1

Molecular Formula

C21H22N4O6S

HBD / HBA

4 / 9

Rotierbare Bindungen

9

Schwere Atome

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

Yes, Raltitrexed is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL225071. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135400182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Raltitrexed auf PillFYI

Struktur

Schnelldaten

Formel: C21H22N4O6S

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.